After 5 years, 666 (86.8%) individuals were followed up. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The average MIND-NL scores for the short FFQ (8·4 ( sd 1·8) points) and food records (6·7 ( sd 1·7) points) showed to be significantly different ( P 0·20) were observed for 10 out of 15 MIND-NL diet components. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
MIND scores were significantly lower in the AD group (P < 0.001). 5 key findings →
Participants: 204 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sleep disturbances are prevalent in patients with Alzheimer' disease (AD), being one of the most troubling symptoms during the progression of disease. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dispositional inward anger expression may increase susceptibility to the detrimental impacts of neighborhood disadvantage on cognitive health. 2 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neighborhood disadvantage in later life is associated with poorer cognition and increased vulnerability to dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A higher GPF was associated with better cognitive function in institutionalized older adults with dementia. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This diet has been shown to improve cognitive function in patients with mild cognitive impairment, Alzheimer’s disease, vascular cognitive impairment, and vascular dementia. 4 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Participant experiences and perceptions formed three themes: (1) aging accelerates PCDS progression, (2) PCDS threatening daily life, and (3) adapting to changes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Physical and cognitive decline significantly affects seniors’ quality of life. 4 key findings →
Participants: 72 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It has been reported that taurine intake in the past may have a positive effect on present cognitive function in the elderly. 4 key findings →
Design: cross-sectional Participants: 481 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
36/100
Frontal contributions to cognitive decline in aging were explored using functional MRI. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive training, physical activity, and exercise have often been reported to improve cognitive performance in older adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent findings suggest a possible role of diet in age-related cognitive decline, and cognitive impairment of both degenerative (Alzheimer's disease, AD) or vascular origin. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive difficulties and gait abnormalities both increase with age. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The unprecedented growth in the number of older adults in our society is accompanied by the exponential increase in the number of elderly people who will suffer cognitive decline and dementia in the next decades. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive decline may lead to dementia whose most frequent cause is Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
CT offers promise as a preventive therapeutic technique in healthy older adults and particularly as a secondary prevention method for "at risk" groups. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cognitive decline in elderly people often derives from the interaction between aging-related changes and age-related diseases and covers a large spectrum of clinical manifestations, from intact cognition through mild cognitive impairment and dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Converging lines of research indicate that complex mental activity is associated with reduced dementia risk. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this review was to update available knowledge on the relationship between adherence to the Mediterranean diet (MeDi) and cognitive decline, risk of dementia or Alzheimer's Disease (AD), and to analyse the reasons for some inconsistent results across studies. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
As the population ages, risks for cognitive decline threaten independence and quality of life for older adults and present challenges to the health care system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
There have been increasing efforts to develop cognitive interventions to ameliorate cognitive problems experienced by older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Adherence to a Mediterranean diet has recently been shown to protect against cognitive decline and dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a pressing demand for improving the quality and efficacy of health care and social support services needed by the world's growing elderly population, especially by those affected by mild cognitive impairment (MCI) and Alzheimer's disease (AD)-type early-stage dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,130 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Cognitive Function in Individuals With Physical Frailty but Without Dementia or Cognitive Complaints: Results From the I-Lan Longitudinal Aging Study
- Preclinical AD predicts decline in memory and executive functions in subjective complaints
- Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
- Cognitive Decline and Its Risk Factors in Prevalent Hemodialysis Patients
- Food Insecurity and Cognitive Trajectories in Community-Dwelling Medicare Beneficiaries 65 Years and Older
- Body mass index, lifestyles, physical performance and cognitive decline: the "Treviso Longeva (TRELONG)" study
- Effects of Transcranial Pulse Stimulation (TPS) on Adults with Symptoms of Depression-A Pilot Randomized Controlled Trial
- Association Between Lifestyle at Different Life Periods and Brain Integrity in Older Adults
- Interventions for subjective cognitive decline: systematic review and meta-analysis
- Effects of a moderate-intensity aerobic exercise programme on the cognitive function and quality of life of community-dwelling elderly people with mild cognitive impairment: A randomised controlled trial
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →